FDA Approval International Molecular Biology 
Drug Target Review
JUNE 5, 2025
Currently, three FDA-approved disease-modifying drug therapies are available: hydroxyurea, crizanlizumab and L-glutamine, though each has limitations that affect patient compliance. The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease. JAMA Netw Open. 2023 Nov 1;6(11):e2344546.
Codon
JUNE 5, 2025
The treatment, now known as Casgevy, became the first CRISPR-based therapy to gain FDA approval, in 2023. Gray, in London to discuss the significance of her recovery at the Third International Summit on Human Genome Editing , described Casgevy as “a new beginning for people with sickle cell disease.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
MAY 27, 2024
At a base-layer, Caris’ comprehensive molecular profiling that we perform for patients today can identify predictive biomarkers for current FDA-approved ADCs. His work has been published in many high-impact journals and presented at international oncology meetings. Examples include HER2-low and FOLR1.
Broad Institute
APRIL 25, 2024
The project is a collaboration between the Broad and the African Center of Excellence for Genomics of Infectious Diseases (ACEGID) at Redeemer’s University outside Lagos in Nigeria, where Happi is a professor of molecular biology and genomics. Sooner than planned, Sentinel would be put to the test.
Codon
JUNE 18, 2024
Klebahn placed the algae cells into an enclosed chamber beneath his light microscope, and then pumped in air until its internal pressure rose to twice, then three-times, normal atmospheric levels. By measuring the length of time that it takes for a soundwave to enter and return, an ultrasound device constructs an internal image of the body.
The Pharma Data
JANUARY 21, 2021
Through its world-class competitions, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair, the Broadcom MASTERS, and its award-winning magazine, Science News and Science News for Students, Society for Science is committed to inform, educate, and inspire.
Drug Target Review
FEBRUARY 15, 2024
Advances in molecular biology have led to highly safe, efficient, and effective platforms, such as mRNA, that can be rapidly re-purposed for different pathogens, multiple pathogens, or new strains of evolving pathogens. He currently serves as Chief Medical Officer at SIGA Technologies. References Morens D, Fauci A.
Expert insights. Personalized for you.
Let's personalize your content